Expansion momentum Cambrex is rapidly expanding its manufacturing footprint in the US and Europe, including new API plants in Charles City, Iowa, and a Milan expansion, signaling growing capacity and opportunity for CDMO partnerships.

Investment drive Significant capital deployment across facilities and R&D capabilities (up to 150 million) indicates a strategic push to enhance small-molecule and peptide services, presenting upsell potential for complex APIs and early development partnerships.

Headcount growth Plans to add hundreds of roles in 2028 suggest ongoing scale of operations, creating opportunities for turnkey services, vendor onboarding, and supply chain collaboration to support increased output.

Global reach With operations spanning North America and Europe and a 40-year track record as a trusted CDMO, Cambrex presents a broad market footprint ideal for multi-region development and manufacturing programs.

Recognition and focus Industry recognition (Snapdragon Prize) and emphasis on comprehensive API development and manufacturing across the drug lifecycle point to partnerships around IND enabling, analytics, and complex molecule capabilities.